Related Experiment Video
Updated: Jun 15, 2026
07:36
Isolation of Human Lymphatic Endothelial Cells by Multi-parameter Fluorescence-activated Cell Sorting
Published on: May 1, 2015
Lymphangioleiomyomatosis and TSC2-/- cells
Thomas N Darling1, Gustavo Pacheco-Rodriguez, Alfredo Gorio
1Department of Dermatology, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814, USA. tdarling@usuhs.mil
Lymphatic Research and Biology
|March 19, 2010
Summary
Pulmonary lymphangioleiomyomatosis (LAM) and renal angiomyolipomas (AMLs) cells are heterogeneous. Researchers are developing better models using TSC2-deficient cells for LAM and AML studies.
Area of Science:
- Cell biology
- Genetics
- Oncology
Background:
- Pulmonary lymphangioleiomyomatosis (LAM) and renal angiomyolipomas (AMLs) are rare diseases characterized by heterogeneous cell populations.
- These cells exhibit differentiation towards smooth muscle, fat, and vascular lineages.
- Mutations in TSC1 or TSC2 genes are implicated in the pathogenesis of LAM and AMLs.
Purpose of the Study:
- To investigate the heterogeneity of cells in LAM and AMLs.
- To explore the utility of TSC2-deficient cells in disease modeling.
- To highlight the need for improved methods to derive and characterize TSC2-deficient cells from human tumors.
Main Methods:
- Analysis of cell heterogeneity in LAM and AMLs.
- Derivation and characterization of TSC2-deficient cells from human tumors and Eker rat leiomyomas (ELT3 cells).
- Utilizing rodent cell models for LAM.
Main Results:
- LAM and AML cells are heterogeneous, with varying differentiation patterns.
- Discovery of TSC1/TSC2 mutations enables discrimination between affected and neighboring cells.
- Successful derivation of TSC2-deficient cells from specific tumors, including ELT3 cells, for LAM modeling.
Conclusions:
- Understanding cell heterogeneity is crucial for LAM and AML pathogenesis.
- TSC2-deficient cells, particularly those derived from human tumors, are valuable tools for disease modeling.
- Advancements in culturing well-characterized TSC2-deficient human tumor cells are essential for developing effective in vitro and in vivo models for LAM research and treatment development.
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
02:17The Tumor Microenvironment
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...